
    
      The primary objective of this study is assess the efficacy of motavizumab compared to placebo
      when administered monthly by intramuscular (IM) injection during the first RSV season for the
      reduction of the incidence of serious early childhood wheezing in preterm infants between
      their 2nd and 3rd birthdays.
    
  